Skip to main content

Table 1 Study patients: demography and baseline characteristics (all patients)

From: Safety of three different product doses in autologous chondrocyte implantation: results of a prospective, randomised, controlled trial

Dose group
Dose [spheroids/cm2]
Low Medium High All patients
3–7 10–30 40–70
N = 25 N = 25 N = 25 N = 75
Sex
 Female 8 4 10 22
 Male 17 21 15 53
Age [years] 33 ± 10 34 ± 9 34 ± 9 34 ± 9
BMI
 [kg/m2] 24.9 ± 2.5 25.6 ± 3.2 25.1 ± 3.6 25.2 ± 3.1
 Range 21.3–29.8 19.4–33.2 19.0–32.3 19.0–33.2
Defect size
 [cm2] 4.8 ± 1.5 4.9 ± 1.3 5.2 ± 1.3 5.0 ± 1.9
 Range 0.5a–7.5 1.3a–7.5 3.0a–8.0 0.5a–8.0
Defect size group
 4–6.99 cm2 22 22 21 65
 7–10 cm2 3 3 4 10
Defect location (primary)
 Femur 9 10 9 28
 Tibia
 Patella 16 15 16 47
  1. Numbers of patients or mean ± SD, or where appropriate the range (minimum–maximum), are given
  2. aValue outside allowed range